Candriam S.C.A. Esperion Therapeutics, Inc. Transaction History

Candriam S.C.A.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Jan 22, 2021	SELL	$24.2 - $35.76 $2.32 Million - $3.43 Million	-95,955 Closed	0 $0
Q3 2020 Oct 19, 2020	SELL	$31.18 - $52.71 $650,071 - $1.1 Million	-20,849 Reduced 17.85%	95,955 $3.57 Million
Q2 2020 Jul 23, 2020	SELL	$30.04 - $51.31 $2.95 Million - $5.04 Million	-98,292 Reduced 45.7%	116,804 $5.99 Million
Q4 2019 Jan 21, 2020	BUY	$35.4 - $59.82 $7.61 Million - $12.9 Million	215,096 New	215,096 $13,000
Q4 2018 Feb 14, 2019	SELL	$36.99 - $59.11 $1.11 Million - $1.77 Million	-30,000 Closed	0 $0
Q1 2018 May 09, 2018	SELL	$65.94 - $80.76 $3.63 Million - $4.44 Million	-55,000 Reduced 64.71%	30,000 $2.17 Million
Q4 2017 Feb 07, 2018	BUY	$43.47 - $67.43 $217,350 - $337,150	5,000 Added 6.25%	85,000 $5.6 Million
Q3 2017 Nov 03, 2017	BUY	$43.8 - $52.77 $3.5 Million - $4.22 Million	80,000	80,000 $4.01 Million

206

128M

1.63M

930K

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $140M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.